Date: 2016-01-29
Type of information: Initiation of development program
phase: 1
Announcement: initiation of development program
Company: Oxford BioMedica (UK) Novartis (Switzerland)
Product: CAR-T cell programme
Action
mechanism: cell therapy/immunotherapy product/gene therapy/CAR-T cell
Disease: undisclosed
Therapeutic area: undisclosed
Country:
Trial details:
Latest
news: * On January 29, 2016, Oxford BioMedica announced that the Group has initiated work on a second Chimeric Antigen Receptor T cell (CART) programme for an undisclosed indication. Under an agreement signed with Novartis in October 2014, Oxford BioMedica will undertake process development and manufacturing for the lentiviral vector associated with the new programme. Oxford BioMedica is currently manufacturing lentiviral vector expressing CTL019 for Novartis and carrying out process development work to establish the next-generation manufacturing process. The Group also granted Novartis a non-exclusive licence in oncology under the Group’s LentiVector® platform and an exclusive licence for the worldwide development and commercialisation of all CART cell products arising from the process development collaboration. In return, Oxford BioMedica will receive undisclosed royalties on potential future sales of CART products covered by the agreement.
